Want to join the conversation?
In 3Q15, $ICPT announced the initiation of its REGENERATE Phase 3 trial, this is the first phase Phase 3 registrational trial in non-cirrhotic NASH patients with fibrosis, a serious chronic liver disease with no approved therapies. $ICPT is targeting enrollment of 1,400 biopsy-proven NASH patients with stage 2 and stage 3 fibrosis.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)